Variable | Perioperative Transfusion: Yes (N=51) Mean (SD) | Perioperative Transfusion: No (N=15) Mean (SD) | P-value |
---|---|---|---|
Age | 69.0 (11.46) | 71.1 (9.60) | 0.5278 |
BMI | 28.0 (7.31) | 26.7 (5.68) | 0.5183 |
Histology: | |||
High grade pap serous | 46 | 14 | 0.299 |
Low grade | 2 | 0 | |
Mucinous | 1 | 0 | |
Clear cell | 2 | 0 | |
Endometrioid | 0 | 1 | |
Pre-treatment CA125 | 3013.4 (5833.6) | 2156.9 (2897.4) | 0.5863 |
Pre-operative CA125 | 198.8 (401.6) | 462.8 (1585.2) | 0.2822 |
Normal Pre-op: | |||
Yes | 11 | 9 | 0.005 |
No | 39 | 6 | |
Delta CA125 | 2867.5 (5702.6) | 1694.2 (1592.9) | 0.4361 |
Pre-op Clinical Stage: | |||
Stage 3 | 36 | 11 | 0.992 |
Stage 4 | 13 | 4 | |
Pre-op Chemo: | 0.907 | ||
Carboplatin/Paclitaxel | 41 | 13 | |
Carbo/taxol/bevacizumab | 5 | 1 | |
Other | 4 | 1 | |
Dose-dense Taxol: | 0.258 | ||
Yes | 4 | 0 | |
No | 46 | 15 | |
Pre-op Chemotherapy cycle # | 0.21 | ||
3 or less | 37 | 8 | |
< 3 | 14 | 7 | |
Optimal Cytoreduction: | 0.812 | ||
No visible | 12 (23.5%) | 5 (33.3%) | |
1-5mm | 9 (17.6%) | 3 (20%) | |
≤1cm | 22 (43.1%) | 6 (40%) | |
Suboptimal | 7 (13.7%) | 1 (6.7%) | |
Final Stage: | 0.646 | ||
Ic | 1 | ||
IIIc | 38 | 10 | |
IVa | 8 | 4 | |
IVb | 4 | 1 | |
Pre-op HgB (g/dL) | 10.5 (0.16) | 11.5 (0.44) | 0.0091 |
Operative blood loss (mL) | 613.7 (421 ) | 283.3 (144.7 ) | 0.004 |
Number of Units Transfused | |||
zero units | 0 | 15 | |
1-3 units | 36 | 0 | |
4-7 units | 15 | 0 | |
Days to death | 662.9 (65.7) | 865.8 (177.6) | 0.1959 |
Alive: | 0.918 | ||
Yes | 14 | 4 | |
No | 35 | 10 |